Abstract Number: 499 • 2012 ACR/ARHP Annual Meeting
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Background/Purpose: Recent recommendations have suggested higher starting doses of methotrexate, i.e. 15 mg/week (3E initiative) in rheumatoid arthritis. However, studies comparing conventional (7.5mg) and newer…Abstract Number: 500 • 2012 ACR/ARHP Annual Meeting
Comparison of Tolerability Between Tumor Necrosis Factor-Inhibitors and Tocilizumab for the Treatment of Rheumatoid Arthritis
Background/Purpose: Some patients with rheumatoid arthritis (RA) receiving tumor necrosis factor-inhibitors (TNF-Is) show inadequate response to TNF-Is. But it has not been clarified what is…Abstract Number: 501 • 2012 ACR/ARHP Annual Meeting
TNF Inhibitor Treatment in Rheumatoid Arthritis (RA) Patients with Moderate Versus High Disease Activity At Baseline: A Comparison of Utility Gains, Response and Remission Rates
Background/Purpose: Randomized clinical trials in RA have until recently focused on patients (pts) with high disease activity, but the majority of pts in the clinic…Abstract Number: 502 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement
Background/Purpose: Lung involvement is common in patients with Rheumatoid Arthritis (RA), including interstitial lung disease (ILD), pleural disease and small airway disease. There are no…Abstract Number: 503 • 2012 ACR/ARHP Annual Meeting
Safety Update On Certolizumab Pegol in Patients with Active Rheumatoid Arthritis with Long Term Exposure
Background/Purpose: The safety of certolizumab pegol (CZP) in rheumatoid arthritis (RA) has been reported in previous pooled analyses of clinical trials. An update of long-term…Abstract Number: 504 • 2012 ACR/ARHP Annual Meeting
Pathogenic Autoantibodies to the Anti-Muscarinic Type 3 Receptor Act by Competitive Inhibition of Acetylcholine-Mediated Receptor Signalling in Sjögren’s Syndrome
Background/Purpose: Primary Sjögren’s syndrome (SS) is a systemic autoimmune disorder characterized by exocrine failure and widespread autonomic dysfunction. Functional autoantibodies (Abs) directed against the muscarinic…Abstract Number: 505 • 2012 ACR/ARHP Annual Meeting
Characterization of an in Vitro Model of Human Salivary Gland for Studying Sjögren Syndrome (SS)
Background/Purpose: Sjögren's syndrome (SS) is an autoimmune exocrinopathy of unknown etiology that is characterized by decreased salivary secretion (xerostomy) and lacrimal (xerophthalmy). Histopathological lesions…Abstract Number: 506 • 2012 ACR/ARHP Annual Meeting
Ebv-Mir-Bart13 Affects the Expression of AQP5 in Human Salivary Gland Cell Lines Contributing to the Pathogenesis of Sjögren’s Syndrome
Background/Purpose: Loss of secretory function of salivary glands is one of the most important functional effects of Sjögren’s syndrome (SS), a chronic systemic autoimmune disease.…Abstract Number: 507 • 2012 ACR/ARHP Annual Meeting
Expression of Micrornas (miRNAs) Predicted to Target Ro/SSA and La/SSB Autoantigens in Sjögren’s Syndrome (SS)
Background/Purpose: microRNAs (miRNAs) are key post-transcriptional regulators of gene expression and might be implicated in the over-expression of Ro/SSA and La/SSB autoantigens in the salivary…Abstract Number: 508 • 2012 ACR/ARHP Annual Meeting
TLR3-Signaling Induces the Expression of Ro/SSA and La/SSB Autoantigens in Salivary Gland Epithelial Cells (SGECs)
Background/Purpose: Previous studies have shown that the mRNA expression levels of the Ro52/TRIM21, Ro60/TROVE2 and La/SSB intracellular autoantigens are elevated within the immunopathologic lesions of…Abstract Number: 509 • 2012 ACR/ARHP Annual Meeting
IL-7 and Toll-Like Receptor 7 Synergistically Increase Th1/Th17/Th22 Cytokine Secretion and Activity of B Cells
Background/Purpose: IL-7 is a potent T cell activating cytokine that has been shown to cause proliferation, survival and differentiation of T cells as well as…Abstract Number: 470 • 2012 ACR/ARHP Annual Meeting
Concomitant Assessment of Clinical and Ultrasound Efficacy and Safety of Tocilizumab in Patients with Moderate to Severe Rheumatoid Arthritis: The Torpedo Study
Background/Purpose: The anti-IL6-R tocilizumab (TCZ), indicated for the treatment of moderate to severe rheumatoid arthritis (RA), has demonstrated its clinical and structural efficacy in phase…Abstract Number: 471 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs
Background/Purpose: This study evaluated golimumab (GLM) as add-on therapy in patients with active RA despite treatment with non-biologic DMARDs. Two GLM treatment strategies (subcutaneous [SC]…Abstract Number: 472 • 2012 ACR/ARHP Annual Meeting
More Positive Expectations of Treatment with Golimumab for Rheumatoid Arthritis Are Associated with Greater Improvement in Clinical Outcomes
Background/Purpose: Little is known about how patient and physician expectations relate to clinical outcomes. This study investigated the expectations that patients and physicians have at…Abstract Number: 473 • 2012 ACR/ARHP Annual Meeting
The Addition of Another Disease-Modifying Anti-Rheumatic Drug to Methotrexate in Place of Infliximab Reduces the Flare Rate During 2 Years After Infliximab Discontinuation in Patients with Rheumatoid Arthritis
Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) should be divided into remission-induction phase and its maintenance phase. To date, the usefulness of the combination…